NATCO Pharma Ltd gets approval from its Board of Directors for increasing its stake in Adcock Ingram Holdings Proprietary Ltd to 49%

NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") has announced that its Board of Directors has approved to acquire additional shareholding in Adcock Ingram Holdings Proprietary Limited ("Adcock Ingram") subject to customary closing conditions and statutory compliances. This acquisition valued at ₹ 1,069 crores at the prevailing exchange rate will take NATCO's shareholding in Adcock Ingram from 35.75% to 49%.

Adcock Ingram has delivered a topline of US$ 423 million with an EBITDA of ~US$ 59 million for the period ending 9 months on March 31, 2026. Post transaction, NATCO will be recognising 49% of profit after tax of Adcock Ingram in its books.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 983.55 as compared to the previous close of Rs. 961.45. The total number of shares traded during the day was 30172 in over 1950 trades.

The stock hit an intraday high of Rs. 987.95 and intraday low of 947.95. The net turnover during the day was Rs. 29211038.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 Pharmaceuticals Approval StakeIncrease AdcockIngramHoldingsProprietary